asianprimenews
Breaking News
Breaking NewsGeneralPublic Interest

Honasa Consumer Limited Initial Public Offer to open on October 31st, 2023 Turns Profitable in Q1-FY 2024

by asianprimenews0681


L to R: Jayasankar Venkataraman (Managing Director and Member of the Board Kotak Mahindra Capital Company), Abhinav Bharti (Managing Director, Head of India ECM, J.P. Morgan India Pvt Ltd), Raman Preet Sohi (CFO, Honasa Consumer Ltd.), Varun Alagh (Chairman, Wholetime Director and CEO, Honasa Consumer Ltd.), Ghazal Alagh (Wholetime Director and Chief Innovation Officer, Honasa Consumer Ltd.), Cheryl Netto (Deputy Chief Executive Officer, JM Financial) and Rahul Saraf (Managing Director, Head of India Investment Banking, Citigroup Global Markets India Private Limited) at the IPO conference of Honasa Consumer Ltd.

Honasa Consumer Limited (“HCL” or the “Company”), proposes to open on Tuesday, October 31, 2023, an initial public offer of equity shares of face value of ₹10 each (“equity shares”) of Honasa Consumer Limited (“Company” or “Issuer”).

The company has turnaround in the Q1-FY 2024 reporting net profit of Rs. 24.71 crore against Rs. 11. 52 crores in Q1-FY 2023 and FY 2023 net loss of Rs. 151 crores.

The gross profit margin of 17.03 % in Q1-FY 2024 allows a high profit poll to leverage as cost efficiency set in. The company is on the cusp of increase in profitability trajectory with business model efficiency and operating leverage setting in.

The total offer size comprises of fresh issue aggregating up to ₹ 365 crore Equity Shares and Offer for Sale (OFS) of up to 41,248,162 Equity Shares by Selling Shareholders. (“The Total Offer Size”). Those offering shares in the OFS include promoters and founders — Varun Alagh and Ghazal Alagh — and investors like Fireside Ventures Fund, Sofina, Stellaris, Kunal Bahl, Rohit Kumar Bansal, Rishabh Harsh Mariwala and Bollywood actor Shilpa Shetty Kundra.

The Offer will close on Thursday, November 2, 2023.

The Price Band of the Offer has been fixed at ₹ 308 to ₹ 324 per Equity Share. Bids can be made for a minimum of 46 Equity Shares and in multiples of 46 Equity Shares thereafter. Discount of ₹ 30 per equity share is being offered to eligible employees bidding in the employee reservation portion

The Company, as part of the Objects of the Offer, proposes to utilize the Net Proceeds raised through the Fresh Issue towards (i) Advertisement expenses towards enhancing the awareness and visibility of brands, (ii) Capital expenditure to be incurred by Company for setting up new EBOs, (iii) Investment in its Subsidiary, Bhabani Blunt Hairdressing Private Limited (“BBlunt”) for setting up new salons; and (iv) General corporate purposes and unidentified inorganic acquisition. (Collectively, the “Objects”).

Kotak Mahindra Capital Company Limited, Citigroup Global Markets India Private Limited, JM Financial Limited and J.P. Morgan India Private Limited are the Book Running Lead Managers to the offer.

About The Company:
Honasa Consumer Limited is the largest digital-first beauty and personal care (“BPC”) company in India in terms of revenue from operations for the Financial Year 2023 (Source: RedSeer Report). Since its inception, Honasa Consumer has worked with the primary objective of developing products that address beauty and personal care problems faced by consumers. Company’s flagship brand, Mamaearth, is built to service a core customer need for safe-to-use, natural products, and focuses on developing toxin-free beauty products made with natural ingredients. According to the RedSeer Report, as of the Financial Year 2023, Mamaearth has emerged as the fastest growing BPC brand in India to reach an annual revenue of ₹10 billion (in the preceding 12 months) within six years of launch.

Since launching Mamaearth in 2016, Honasa has added five new brands to its portfolio, namely The Derma Co., Aqualogica, Ayuga, BBlunt and Dr. Sheth’s, and have built a ‘House of Brands’ architecture. As of June 30, 2023, company’s portfolio of brands with differentiated value propositions includes products in the baby care, face care, body care, hair care, color cosmetics and fragrances segments.

As per RedSeer Report, Honasa Consumer is the largest company in the DTC BPC market in India in terms of revenue generated from the DTC channel in Financial Year 2023. Its brand Mamaearth was ranked amongst the top three in terms of awareness in the grooming category on Flipkart between May 2021 and July 2023 and Mamaearth was India’s most-searched BPC brand on Google Trends between January 2020 and June 2023.

The Company makes products available to customers through Omni-channel distribution networks across both online and offline touchpoints. Its modern trade channel includes a network of 31 retail chains, as of June 30, 2023, with whom it has contractual arrangements for the sale of products. These retail chains include national retail chains, regional retail chains, pharmacies, and cash-and-carry stores across India. For the period of July 2023, the Company is estimated to have retailed products through 154,447 FMCG retail outlets in India. Its offline channel consists of general trade channels and modern trade retail channels, and is supplemented by 85 EBOs across India as of June 30, 2023. The Company accesses this channel through its network of distributors, super distributors and sub-stockiest (total of 220 by FY23).

Honasa continuously seek to connect better with its consumers and strengthen its brand equity by building ‘purpose driven’ brands that are associated with environmental and social impact causes. Through the Mamaearth ‘Plant Goodness’ initiative, company work with a non-government organisation to plant trees for orders placed on its direct-to-consumer (“DTC”) platform and share geo-tagged images of these trees with its consumers. Similarly, The Derma Co. is associated with a ‘Young Scientists’ program wherein children in certain rural parts of India are provided with access to education in science, and Aqualogica is associated with a ‘Fresh Water for All’ initiative wherein company help enable access to clean drinking water for marginalized communities.

Disclaimer:

Share

Related posts

ICICI Lombard launches a slew of 14 new products across Health, Motor and Corporate segments

asianprimenews

Why CML Isn’t a Solved Disease—And What Patients in India Need to Know* Over the past two decades, Chronic Myeloid Leukemia (CML) has undergone a transformation—from being a life-threatening condition to one that can be controlled with oral medication. Although survival rates have improved significantly, the idea of CML as a ‘manageable’ disease is now being questioned. Clinicians and patients alike are recognizing that the existing standard of care does not address the full picture—especially for India’s younger patient population, whose needs go far beyond survival. Dr Subhaprakash Sanyal Director of Haematology and BMT Services, Fortis Hospital, Mumbai, said, “There’s a common belief that starting treatment for CML means the journey is simple, but that isn’t the case. Many patients struggle to reach their treatment milestones as expected, and a significant portion need to change or stop their medication due to side effects or intolerance. In fact, about 30 to 40% discontinue their initial therapy within five years, highlighting that the standard approach doesn’t work for everyone.” CML disproportionately affects younger adults in India, where the median age of diagnosis is between 35 and 40 years—much younger than the average age of 50–60 in Western countries. At this life stage, patients are often building careers, supporting families, and planning long-term futures. In this context, treatment is no longer just about survival—it’s about maintaining energy, emotional well-being, professional productivity, and daily independence. Historically, the primary treatment goal in CML was achieving Major Molecular Response (MMR). But over the years, these goals have evolved. Today, physicians aim for deeper responses, particularly Deep Molecular Response (DMR). Achieving DMR paves the way for Treatment-Free Remission (TFR), where patients can potentially stop therapy altogether and remain in remission under medical supervision. These advanced milestones are particularly relevant to newly diagnosed patients, as reaching DMR within the first two years greatly improves the likelihood of achieving TFR down the line. Why So Many Patients Fall Short Despite clear treatment goals, a significant proportion fail to achieve MMR within the first year, and even fewer reach DMR by year two. One of the primary reasons is the impact of persistent, low-grade side effects—such as fatigue, joint pain, and gastrointestinal issues—which patients often tolerate silently but which meaningfully reduce their quality of life. These side effects also drive nonadherence, dose modifications, and ultimately treatment discontinuation. In fact, treatment intolerance is the leading cause of therapy discontinuation in the first two years of CML management. Adding to the complexity, current treatments—particularly ATP-competitive tyrosine kinase inhibitors (TKIs)—can affect not just the intended target but also unrelated biological pathways, causing off-target toxicity. This often leads to therapy switches, a strategy that increases both clinical and emotional burden without necessarily resolving the issue. A recent Indian analysis noted that nearly all CML patients report some form of low-grade side effect, many of which disrupt work and personal life but don’t qualify for hospitalization. As a result, patients feel caught in a difficult balance—managing a chronic illness while enduring ongoing discomfort or disruptions. The Case for Better-Tolerated, More Effective Therapies As the treatment landscape evolves, the need for therapies that not only offer deeper molecular responses but also better tolerability is becoming increasingly clear. Emerging therapies with novel mechanisms of action have begun to change the paradigm by offering comparable—or even superior—efficacy alongside fewer adverse events and lower discontinuation rates. In one international phase III trial, a newer therapy demonstrated a 74.1% MMR rate at 96 weeks, significantly higher than the 52.0% achieved by older therapies. It also showed a 54% lower risk of treatment discontinuation due to side effects, while nearly half of patients achieved MR4 and 30.9% achieved MR4.5, the deepest levels of response. These findings suggest that treatment no longer needs to be a trade-off between efficacy and day-to-day functioning. This shift is particularly important in the Indian context, where younger patients face the possibility of decades-long treatment. For them, the ability to tolerate therapy comfortably while still achieving long-term disease control is not a luxury—it’s a necessity. The Importance of Proactive Conversations Many patients continue older treatments unaware that newer, more tolerable options exist. This makes open doctor–patient conversations crucial—especially early in treatment. Patients should understand their goals, like DMR or TFR, and how their therapy aligns with them. Discussing side effects, lifestyle impact, and alternatives helps ensure care is not just effective, but sustainable and suited to their lives. While CML outcomes have improved, challenges remain—particularly for India’s younger patients. As treatment goals expand and better options emerge, the focus must shift from merely managing the disease to helping patients live well. The future of CML care lies in deeper responses, better tolerability, and enabling life beyond medication.

asianprimenews

Serendipity Arts Festival 2022 to enthrall Goa with dance, theatre and music performances

asianprimenews